1642853-67-5 Usage
Uses
Used in Pharmaceutical Industry:
Dabigatran iMpurity F is used as an impurity in the development and manufacturing process of Dabigatran, a direct thrombin inhibitor. Its presence is crucial for the assessment of the purity and efficacy of Dabigatran, ensuring the safety and effectiveness of the final drug product for antithrombotic applications.
Used in Research and Development:
Dabigatran iMpurity F is utilized as a research compound for studying the properties and interactions of thrombin inhibitors. This helps in understanding the mechanism of action, potential side effects, and the development of new therapeutic strategies for treating conditions related to thrombosis.
Used in Quality Control and Regulatory Compliance:
Dabigatran iMpurity F is employed in quality control processes to ensure that the final Dabigatran product meets the required standards for purity and potency. It is also used in regulatory compliance to demonstrate the safety and efficacy of Dabigatran as a direct thrombin inhibitor in the treatment of thrombotic disorders.
Check Digit Verification of cas no
The CAS Registry Mumber 1642853-67-5 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,6,4,2,8,5 and 3 respectively; the second part has 2 digits, 6 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 1642853-67:
(9*1)+(8*6)+(7*4)+(6*2)+(5*8)+(4*5)+(3*3)+(2*6)+(1*7)=185
185 % 10 = 5
So 1642853-67-5 is a valid CAS Registry Number.
1642853-67-5Relevant academic research and scientific papers
Synthesis method of pradaxa technological impurity
-
Paragraph 0009; 0028-0037, (2018/11/03)
The invention provides a synthesis method of a pradaxa technological impurity. The invention relates to a synthesis method of N-[(1-methyl-2-oxo-2,3-dihydro-1H-benzimidazole)-5-carbonyl]-N-2-pyridyl-3-ethyl propionate; a chemical formula is as follows: the formula is shown in the description; the synthesis method comprises the following steps: 1) stirring and heating a compound SM02 and a compoundCDI in a solvent to react; 2) after reaction is finished, cooling a reaction solution to room temperature or lower; carrying out post-treatment to obtain a compound DB02-1m crude product, wherein thesolvent is one of tetrahydrofuran, 1,4-dioxane, dichloromethane, chloroform, toluene and xylol.
